Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma-n1
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intralesional, Intramuscular, Intravenous, Subcutaneous
01
Overview
Interferon gamma-n1 (Ogamma) is a natural human interferon-gamma preparation co-developed by Otsuka Pharmaceutical and Hayashibara. It is a type II interferon purified from human leukocytes or myelomonocytic cells. It acts as an immunomodulator and biological response modifier by binding to the heterodimeric interferon-gamma receptor (IFNGR1/IFNGR2), which activates the JAK-STAT signaling pathway. This cascade enhances macrophage oxidative metabolism, antibody-dependent cellular cytotoxicity (ADCC), and natural killer (NK) cell activity, while upregulating major histocompatibility complex (MHC) class I and II expression. Interferon gamma-n1 was approved in Japan in 1997 for the treatment of mycosis fungoides (cutaneous T-cell lymphoma).
- Brand names
- OGamma 100OGamma100OGamma-100Ogamma
- Other names
- immune interferoninterferon-gamma-n1interferon-gamma-n-1interferon-gamma-n 1natural human interferon gammanatural human interferon-gammanatural interferon gammanatural interferon-gammatype II interferon
02
Targets
IFNGR2 (Interferon gamma receptor 2)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on interferon gamma-n1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma-n1.